Nature Medicine

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Nature Medicine
May 1, 2025, 09:49 | Blog
Jia (Jenny) Liu Congratulates Herbert Loong on AACR25 and Nature Medicine Publication
Jia (Jenny) Liu, Translational Researcher at The Kinghorn Cancer Centre, shared a post on X: "Congratulations…
Apr 30, 2025, 15:03 | Blog
Posts Not to Miss from AACR 2025: Part 3
The AACR Annual Meeting is one of the biggest events in the world of cancer…
Apr 30, 2025, 10:26 | Science
Herbert Loong: Promising data on D3S-001 at AACR25
Herbert Loong, Chair-Elect of the International Affairs Committee and the Track Leader for Sarcoma (2023)…
Apr 15, 2025, 12:17 | Blog
Bernard A. Fox: Great commentary from Nature Medicine on vaccine hesitancy and the threat presented by the new leadership of HHS
Bernard A. Fox, Co-Founder / President / CEO at UbiVac, shared Saheli Sadanand's post on…
Apr 12, 2025, 12:45 | Blog
Paolo Tarantino: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, posted on X: "Results from OptiTROP-B01 out…
Apr 11, 2025, 22:39 | Insight
Michael Sapienza: FDA Approves Nivolumab/Ipilimumab for Colorectal Cancer
Michael Sapienza, Chief Executive Officer at Colorectal Cancer Alliance, shared the following insightful post on…
Apr 5, 2025, 14:14 | Blog
Katy Rezvani: The Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas
Katy Rezvani, Sally Cooper Murray Chair in Cancer Research at MD Anderson Cancer Center, shared…
Mar 3, 2025, 13:38 | Blog
Tom Fleischer: Liquid Biopsy’s Unseen Limitation
Tom Fleischer, Co-founder & CEO at Sequentify, shared a post on LinkedIn: "Liquid Biopsy’s Unseen…
Feb 25, 2025, 08:29 | Science
Maximilian Merz: What is the biology behind CAR+ T-cell lymphomas?
Maximilian Merz, Head of Early Clinical Trials Unit Leipzig (ECTUL) at Leipzig University, shared an…
Feb 3, 2025, 10:46 | Science
Paolo Cotzia: Tucatinib and trastuzumab with fulvestrant for HR+ patients in heavily pretreated HER2-mut MBC
Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…
Feb 2, 2025, 04:22 | Blog
Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology…
Jan 23, 2025, 13:56 | Science
2 Neoadjuvant chemo-IO trials for high-risk ER+ BC
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared an article by Fatima Cardoso…
Jan 23, 2025, 09:49 | Insight
Angela Mastronuzzi: Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma
Angela Mastronuzzi, President of AIOEP, shared a post on LinkedIn about a recent paper by…
Jan 20, 2025, 02:16 | Science
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Alicia F. C.…
Jan 16, 2025, 22:20 | Blog
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Svetlana Nikic shared on LinkedIn: "New data just out from TRACERx in Nature Medicine showing that…
Jan 15, 2025, 07:40 | Science
Anirban Maitra: The impact of KRAS allelic status on outcomes in Pancreatic Cancer
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center,…
Jan 13, 2025, 17:35 | Insight
UCL and Francis Crick Institute Test Uses Tumor DNA to Predict Lung Cancer Outcomes
Scientists from the Francis Crick Institute, UCL, UCLH, and Personalis have developed a promising new…
Jan 12, 2025, 15:38 | Insight
Danielle Bitterman: TRIPOD-LLM consensus guidelines for reporting LLM research in biomedicine
Danielle Bitterman, Assistant Professor at Harvard Medical School, posted on LinkedIn: “TRIPOD-LLM is out in…
Jan 10, 2025, 15:32 | Science
Danielle Bitterman: Consensus guidelines for reporting LLM research in biomedicine
Danielle Bitterman, Assistant Professor at Harvard Medical School, posted on X about recent paper by…
Jan 7, 2025, 13:06 | Insight
Jasmin Hundal: Bridging the Gap Between Clinical Trials and Real-World Patients in Oncology
Jasmin Hundal, Hematology-Oncology Fellow at Cleveland Clinic and also a Resident Physician at the University…
Jan 6, 2025, 12:40 | Science
Chaitanya Bandlamudi: Detailed clinico-genomic landscape of pancreatic adenocarcinomas
Chaitanya Bandlamudi, Assistant Member at MSK Department of Pathology and Laboratory Medicine, shared a post…
Jan 5, 2025, 14:06 | Science
Erman Akkus: KRAS mutations in pancreatic cancer
Erman Akkus, Medical Oncology fellow at Ankara University, Faculty of Medicine, shared a recent article…
Dec 16, 2024, 17:20 | Insight
João Monteiro: Eleven clinical trials to watch in 2025
João Monteiro, Chief Editor at Nature Medicine, shared on LinkedIn: "It's become an end-of-year tradition…
Dec 16, 2024, 08:50 | Science
Ben Westphalen: PrecisionChain enables secure genetic and clinical data integration
Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, posted the…
Dec 14, 2024, 15:57 | Insight
Shubham Pant: Updated data from the Phase 1 AMPLIFY-201 trial at the ESMO
Shubham Pant, Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas…
Nov 18, 2024, 07:30 | Blog
Sumanta Pal: Amazing City of Hope Medical Oncology Advances Symposium
Sumanta Pal, Expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center, posted…
Nov 16, 2024, 15:57 | Insight
Neoadjuvant nivolumab and relatlimab in locally advanced MSI CRC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and…
Nov 13, 2024, 08:27 | Insight
Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent…
Oct 16, 2024, 14:26 | Blog
Rahul Banerjee: An area where we need more research!
Rahul Banerjee shared a post by Nature Medicine on X, adding the following: “Relevant to…
Oct 6, 2024, 13:26 | Insight
Vivek Subbiah: Fragmentation in medicine harms patients and hinders research
Vivek Subbiah shared a post on LinkedIn about a recent paper "Fragmentation in medicine harms…
Oct 4, 2024, 15:09 | Blog
Phase 3 EVER-002 trial is out
Paolo Tarantino shared an article by Binghe Xu on X: "Phase 3 EVER-002 trial (also…
Oct 1, 2024, 04:54 | Positive
Empowering Women in Oncology: LEAD 2024 Recognized Rana McKay and Nazli Dizman
Dr. Rana McKay and Dr. Nazli Dizman were honored at the LEAD 2024 The Leadership, Empowerment,…
Sep 27, 2024, 16:31 | Insight
Immunotherapy for aggressive breast cancer appears to be effective even without chemotherapy - The Netherlands Cancer Institute
The Netherlands Cancer Institute posted on LinkedIn: "Immunotherapy as a treatment for an aggressive form of…
Sep 22, 2024, 04:57 | Blog
A foundation model for clinical-grade computational pathology and rare cancers detection - Science News
Science News shared a post on X: "A foundation model for clinical-grade computational pathology and rare…
Sep 21, 2024, 15:21 | Insight
Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients
Ulrike Harjes, Senior Editor at Nature Medicine, posted the following on X: “Out now in Nature…
Sep 21, 2024, 09:03 | Blog
Neoadjuvant nivolumab with or without ipilimumab in early stage TNBC
Top Biomedical Science shared a post on X, about recent paper published in Nature Medicine:…
Sep 20, 2024, 13:05 | Insight
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer
Top Biomedical Science shared a post on X about a recent paper by Peter de…
Sep 18, 2024, 09:18 | Insight
34 Posts Not to Miss From ESMO24 Day 4
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 8, 2024, 18:30 | Blog
Ulrike Harjes: Fratricide-resistant CD7-CAR T cells in T-ALL
Ulrike Harjes, Senior Editor at Nature Medicine, posted on LinkedIn about recent paper by Bernice…
Aug 26, 2024, 09:33 | Insight
Using molecular classification to improve surgical and radiotherapy decisions in meningioma
Recently, an article by Justin Wang et al. titled "Molecular classification to refine surgical and…
Aug 26, 2024, 08:35 | Insight
Highlights from The California Cancer Consortium Conference 2024 by Sumanta K. Pal
The California Cancer Consortium Conference is an annual conference that brings together leading oncology experts,…
Aug 25, 2024, 13:02 | Insight
Toni Choueiri: Results from LITESPARK-005 are out
Toni Choueiri shared a post on X about a recent paper titled "Belzutifan versus Everolimus…
Aug 22, 2024, 07:25 | Insight
Bram De Laere: Privileged seeing the ProBio published in Nature Medicine
Bram De Laere, Post doctoral Researcher at Ghent University, shared a post by ProBio on…
Aug 15, 2024, 14:41 | Insight
Vivek Subbiah: Transforming the fragmented silos of medicine into a wheel of collaboration
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared a post by…
Aug 14, 2024, 06:17 | Insight
Sumanta K. Pal: Viable solutions to "fragmentation" in medicine
Sumanta K. Pal shared a post by Vivek Subbiah on X: "Wonderful piece in Nature…
Aug 10, 2024, 13:38 | Insight
Vivek Subbiah: Fragmentation in medicine harms patients and hinders research
Vivek Subbiah shared on LinkedIn: "Just published in Nature Medicine: Fragmentation in medicine harms patients…
Aug 10, 2024, 13:12 | Insight
Piotr Wysocki: Supervised, structured and individualized exercise improves the quality of life for metastatic breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "A recent study published in Nature Medicine, led by Anouk…
Aug 7, 2024, 01:44 | Insight
Celia Dobersalske: Tumour reactive T cells assembling in the proximal cranial bone of patients with glioblastoma
Celia Dobersalske shared a post on X: “Excited to share our new paper out in…
Jul 28, 2024, 13:53 | Blog
Thomas Fuchs: Virchow Foundation Model capable of characterizing the morphology of cancer at unprecedented acuity
Thomas Fuchs,  Department Chair of Artificial Intelligence and Human Health in Icahn School of Medicine…
Jul 27, 2024, 11:23 | Insight
Anouk Hiensch: Exercise improves quality of life in patients with metastatic breast cancer
Anouk Hiensch, Assistant Professor at UMC Utrecht, shared a post on X about his recent…
Jul 27, 2024, 11:09 | Blog
Mark Foundation grantees published 15 papers in top journals In the 2nd quarter of 2024
The Mark Foundation for Cancer Research shared a post on X: “In the 2nd quarter…
Jul 24, 2024, 08:12 | Insight
Meta-analysis of non-relapse mortality post-CAR-T cells in lymphoma and myeloma
Nature Medicine shared on X about a paper titled "A systematic review and meta-analysis of nonrelapse…
Jul 19, 2024, 22:19 | Insight
Yüksel Ürün: Congratulations all new participants of the ASCO Leadership Development Program!
Yüksel Ürün shared a post by Miriam Knoll, on X, adding: "Congratulations to you and…
Jul 19, 2024, 03:24 | Insight
Marc Ramis Castelltort: Fascinating study supporting genome sequencing to all children with cancer
Marc Ramis Castelltort, Managing Partner at Montana, shared a post on LinkedIn about a recent…
Jul 17, 2024, 02:26 | Insight
Patrick Hwu: When patients with solid tumors don’t respond to immunotherapy
Patrick Hwu shared a post on X about a recent paper by Maria Parkhurst et…
Jul 9, 2024, 06:46 | Blog
David Cordas dos Santos: Nonrelapse mortality after CAR-T cell treatment
David Cordas dos Santos, PostDoc at Dana-Farber Cancer Institute, made the following post on X:…
Jul 8, 2024, 17:31 | Insight
Kai Rejeski: Underestimated aspect of CAR T-cell therapy: non-relapse mortality
Kai Rejeski, Visiting investigator at Memorial Sloan Kettering Cancer Center, shared on X: “Hot off…
Jul 5, 2024, 12:37 | Blog
City of Hope is accelerating its microbiome program
City of Hope shared a post on X: “City of Hope is accelerating its microbiome program.…
Jul 4, 2024, 16:27 | Blog
Richard Scott: Exciting to see research carried out via the NHS Genomic Medicine Service
Richard Scott, CEO at Genomics England, shared on LinkedIn: "Really exciting to see research today…
Jul 3, 2024, 23:28 | Insight
Neeraj Agarwal: Amazing performance by the stellar Genitourinary Cancer Research Team's junior investigators
Neeraj Agarwal shared a post on X: "Amazing performance by the stellar Genitourinary Cancer Research…
Jul 3, 2024, 00:52 | Blog
Hedyeh Ebrahimi: Intrigued by the difference in response between CBM588 and ctrl arms
Hedyeh Ebrahimi, Postdoctoral fellow at Genitourinary Cancer Research Team of City of Hope shared a…
Jun 30, 2024, 04:58 | Blog
Victor Moreno: Botensilimab and balstilimab in treating heavily pre-treated patients with MSS mCRC
Victor Moreno, Director of Clinical Research at START Madrid-FJD, shared a post on LinkedIn:  .…
Jun 29, 2024, 14:04 | Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 20, 2024, 12:07 | Insight
Research into why some respond to TKIs better than others - Oncogene Cancer Research
Oncogene Cancer Research recently shared a post on X: "Worth reading this deep dive into…
Jun 19, 2024, 07:50 | Blog
Roger Li: The final results of the CORE001 trial are out now in Nature Medicine
Patrick Hwu shared a post by Roger Li, Urologic oncologist at Moffitt Cancer Center, on…
Jun 18, 2024, 14:13 | Blog
Janice Mehnert: There goes another Mount Sinai Health System resident making waves in oncology
Janice Mehnert, Associate Director For Clinical Research at Perlmutter Cancer Center of NYU Langone Health/NYU Grossman…
Jun 16, 2024, 02:00 | Blog
Justin Stebbing: Activity of botensilimab/balstilimab in patients with metastatic colon cancer
Justin Stebbing shared a post on LinkedIn: "Really interesting paper out today am part of in…
Jun 15, 2024, 07:37 | Blog
Saul Priceman: Phase 1 trial with PSCA-CAR T cell therapy in patients with mCRPC
Saul Priceman, Associate Professor at City of Hope, made the following post on X: "Proud…
Jun 14, 2024, 01:23 | Insight
New Paper Alert! Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab
Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab Authors: Andrea J. Bullock,…
Jun 11, 2024, 14:36 | Blog
Emily Mould: Results from our ZERO Childhood Cancer study have been published in Nature Medicine
Emily Mould, Head of Business Development at Children’s Cancer Institute, shared a post by Children's Cancer…
Jun 8, 2024, 17:22 | Blog
Roger Li: Final results of CORE001 trial at Nature Medicine
Roger Li, Urologic oncologist at Moffitt Cancer Center, shared on X/Twitter: "Final results of CORE001 trial…
Jun 7, 2024, 10:36 | Insight
Vincent Rajkumar: I’m updating my 2024 Review on myeloma for American Journal of Hematology
Vincent Rajkumar shared a post on X: “I’m updating my 2024 Review on myeloma for American…
Jun 2, 2024, 23:47 | Insight
NADINA is one of the 11 clinical studies with the biggest impact on health care in 2024 - Netherlands Cancer Institute
Quoting The Netherlands Cancer Institute on LinkedIn: "The NADINA study, led by researchers from the…
May 23, 2024, 15:09 | Insight
Abhishek D. Garg: Thrilled to share our lab's latest research on multiomics and spatial mapping of immunotherapy responses in kidney cancer patients
Abhishek D. Garg, Head of Laboratory of Cell Stress and Immunity (CSI) at KU Leuven,…
May 23, 2024, 13:01 | Insight
A neural epigenetic signature is prognostic in patients with glioblastoma - Nature Medicine
Nature Medicine recently shared a post on X: "A neural epigenetic signature detectable via plasma…
May 23, 2024, 01:31 | Insight
Danh-Tai Hoang: We developed DEPLOY that predicts DNA methylation and subsequently classifies brain tumors based on histopathology images
Danh-Tai Hoang, a Research Fellow at The Australian National University, recently shared a post on…
May 20, 2024, 14:56 | Insight
Eytan Ruppin: We introduce DEPLOY for the diagnosis of CNS tumor subtypes
Eytan Ruppin, Chief of the Cancer Data Science Lab of the National Institute of Health,…
May 16, 2024, 10:23 | Insight
News and Views from Christine Lovly and Misty Dawn Shields - Nature Medicine
Nature Medicine shared on X: “Refining neoadjuvant immunotherapy for resectable Non- Small Cell Lung Cancer…
May 16, 2024, 09:09 | Blog
Kohei Shitara: Happy to report biomarkers in DESTINIY GC01 at Nature Medicine
Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan shared a post on X:…
May 2, 2024, 15:25 | Blog
Tanja Obradovic: Interesting updates will be coming on ASCO 2024
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON, shared on LinkedIn: "ASCO 2024 is almost…
Apr 29, 2024, 22:33 | Blog
Marleen Kok: Institutional visit by Ulrike Harjes, Senior Editor of Nature Medicine, to The Netherlands Cancer Institute
Marleen Kok, Associate Professor at The Netherlands Cancer Institute, shared a post on X/Twitter: ''Institutional…
Apr 29, 2024, 08:17 | Insight
Bob Li: It was a privilege to lead the first international clinical trial to crack KRAS
Bob Li, Chief Scientific Officer of MSK Direct at Memorial Sloan Kettering Cancer Center, shared…
Apr 25, 2024, 21:25 | Insight
Paper summary by Erman Akkus on TORCH
Erman Akkus, Medicine Oncology and Internal Medicine Specialist at Ankara University, shared on X: “Deep-learning method…
Apr 25, 2024, 12:10 | Blog
Myriam Chalabi: Very happy to host Ulrike Harjes from Nature Medicine
Myriam Chalabi: Medical Oncologist and Cancer Immunotherapy Researcher at Antoni van Leeuwenhoek, The Netherlands Cancer…
Apr 20, 2024, 07:47 | Drugs
Paper summary by Marco Donia
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on…
Apr 13, 2024, 12:22 | Blog
Saheli Sadanand: The potential of Functional Precision Medicine for treatment of Pediatric Cancers
Saheli Sadanand, Deputy Editor of Nature Medicine, shared a post on X: "New Nature Medicine: Excited…
Apr 12, 2024, 17:36 | Insight
Mark Yarchoan: Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 in 2L HCC presented at AACR24
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared on X: "Multicenter P1/2 trial of…
Mar 2, 2024, 12:40 | Blog
David James Pinato: Immunotherapy is truly changing the way we treat HCC
David James Pinato, Director of Developmental Cancer Therapeutics, Clinical Senior Lecturer and Consultant Medical Oncologist…
Feb 21, 2024, 17:21 | Insight
Alex Bick: Excited to share All of Us Research program’s flagship genomics paper
Alex Bick, Assistant Professor of Medicine at Vanderbilt University Medical Center in the Division of…
Feb 15, 2024, 11:05 | Blog
Kohei Shitara: Happy to report ctDNA analysis of PARADIGM at Nature Medicine
Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan, shared a post on…
Jan 29, 2024, 03:56 | Insight
Myriam Chalabi: The Phase 2 PANDA Trial is out in Nature Medicine
Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher at Antoni van Leeuwenhoek, The Netherlands Cancer…
Jan 21, 2024, 18:52 | Insight
Katy Rezvani: Our paper on our Phase I / II trial with cord blood CAR19/IL15 NK cells is published
Katy Rezvani, Chief of Section of Cellular Therapy, Department of Stem Cell Transplantation and Cellular…
Jan 14, 2024, 18:08 | Blog
Vivek Subbiah: The 1st report from the Cancer Programme of the Genomes 100k project
Vivek Subbiah posted on X/Twitter: "Just out Nature Medicine: The 1st report from the Cancer Programme…
Jan 9, 2024, 20:30 | Insight
Pashtoon Kasi: One of the first cancer vaccines that target KRAS
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared a post on X/Twitter:…
Dec 24, 2023, 18:05 | Insight
Marco Donia: Adjuvant Anti-PD-1 Immunotherapy for Resected Melanoma: Update December 2023
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn:…
Dec 5, 2023, 19:09 | Insight
Neeraj Agarwal: Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC prostate cancer
Neeraj Agarwal shared the following on Twitter: “Just in Nature Medicine: Results from Ph3 TALAPRO-2…
Oct 18, 2023, 16:54 | Drugs
Vivek Subbiah: Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on…
Oct 17, 2023, 17:19 | Insight
The limitations of ICB to prevent future cancers in Lynch sydrome - Mike Foote
Mike Foote, GI Medical Oncologist at Memorial Sloan Kettering Cancer Centre, shared on X/Twitter: “Excited…
Oct 11, 2023, 21:48 | Blog
Elsa Anagnostou: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print.
Elsa Anagnostou, Director of Thoracic Oncology Biorepository and Associate Professor of Oncology at Johns Hopkins…
Oct 8, 2023, 17:16 | Blog
Sumanta K. Pal: I'm hugely indebted to Matt Galsky, not just for the chance to be a part of this Nature Medicine masterpiece he drove, but to see the joy of my pts doing well years out from chemo/IO without cystectomy.
12
All: 103 Posts: 1 - 100
Special Coverage